Needham & Company Maintians a 'Hold' on Forest Laboratories (FRX); Q1 Review; Reviewing FDA Calendar
Tweet
Share
E-mailGet Alerts FRX Hot Sheet
Price: $12.00 --0%
Rating Summary:
10 Buy, 12 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
10 Buy, 12 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Needham & Company maintians a 'Hold' on Forest Laboratories (NYSE: FRX).
Analyst, Elliot Wilbur, said, "Despite signaling a shortfall owing to lighter than expected generic Lexapro royalties, FRX’s 1QF13 results still fell modestly short of increasingly diminished expectations. As has been the case for some time however, shares largely get a pass on near-term numbers with expectations largely geared toward real-time movement in the launch trajectory of key new products Viibryd, Daliresp and Teflaro and increasingly upcoming FDA action dates for next in-franchise assets linaclotide and aclidinium."
Wilbur continues to see shares range bound, despite softening financials, but he finds it difficult to see shares reaccelerate into 2013. (FY13 EPS estimate cut from $0.69 to $0.66 and FY14 from $1.70 to $1.68)
For an analyst ratings summary and ratings history on Forest Laboratories click here. For more ratings news on Forest Laboratories click here.
Shares of Forest Laboratories closed at $35.82 yesterday.
Analyst, Elliot Wilbur, said, "Despite signaling a shortfall owing to lighter than expected generic Lexapro royalties, FRX’s 1QF13 results still fell modestly short of increasingly diminished expectations. As has been the case for some time however, shares largely get a pass on near-term numbers with expectations largely geared toward real-time movement in the launch trajectory of key new products Viibryd, Daliresp and Teflaro and increasingly upcoming FDA action dates for next in-franchise assets linaclotide and aclidinium."
Wilbur continues to see shares range bound, despite softening financials, but he finds it difficult to see shares reaccelerate into 2013. (FY13 EPS estimate cut from $0.69 to $0.66 and FY14 from $1.70 to $1.68)
For an analyst ratings summary and ratings history on Forest Laboratories click here. For more ratings news on Forest Laboratories click here.
Shares of Forest Laboratories closed at $35.82 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Keefe, Bruyette & Woods Downgrades Bain Capital Specialty Finance (BCSF) to Market Perform
- Keefe, Bruyette & Woods Downgrades Crescent BDC (CCAP) to Market Perform
- Piper Sandler Starts Dave Inc (DAVE) at Overweight
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, FDARelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
